

TECH CENTER 1600/2900

OCT 22 2001

RECEIVED

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/902,208
Filing Date	07/09/2001
First Named Inventor	Tsai
Group Art Unit	1439 1627
Examiner Name	
Attorney Docket Number	01-06-1685

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	B. CELSA
--------------------	----------

Date Considered	4/21/03
-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number

09/902,208

Filing Date

07/09/2001

First Named Inventor

Tsai

Group Art Unit

1627 1139

Examiner Name

Attorney Docket Number

01-06-1685

RECEIVED
OCT 29 2001
FBI CENTER 1600 2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CIVE OCT 11 2001 PATENT & TRADEMARK OFFICE		KERR, J.F.R. and SEARLE, J., A Suggested Explanation for the Paradoxically slow growth rate of basal-cell Carcinomas..., J. Path., Vol. 107, p.41-44, (1971).	
		MICHAELSON, J., Cell Selection in Development, Biol. Rev. (1987), Vol. 62, p.115-139, Great Britain.	
		WYLLIE, A.H., et. al., Cell Death: The Significance of Apoptosis, International Review of Cytology, Vol. 68, p. 251-306, Academic Press, 1980.	
		COPE, F., et. al., Apoptosis: The Molecular Basis of Cell Death, Cold Spring Harbor Laboratory Press, p.61-86, 1991; "Carcinogenesis and Apoptosis: Paradigms...	
		SU, et.al., FASEB J. Vol. 8, No. 4, Abstract No. 1257, page A218	

Examiner
Signature

B CEC SA

Date

Considered

4/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Aug 8 2002

1600 | 2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	09/902/208
Filing Date	7 /09/2001
First Named Inventor	Tsai
Group Art Unit	1639 4627
Examiner Nam	
Attorney Docket Number	01-06-1685

Sheet	1	of	4
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	B. C. C. S. A	Date Considered	4/21/03
-----------------------	---------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



COPY OF PAPERS
ORIGINALLY FILED

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/902,208
		Filing Date	7/09/2001
		First Named Inventor	Tsai
		Group Art Unit	1627-1639
		Examiner Name	
Sheet 2 of 4	Attorney Docket Number	01-06-1685	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
M C		WANG et al., Oncogene, Vol. 15 pp. 143-157, Sep. 1997	
		LIN, et al., "In Vitro Apoptosis in the Human Hepatoma Cell Line Induced by Transforming Growth Factor B ₁ ", Cancer Research 52(1992) 385-388	
		GROTENDORST, et al., "Attachment of Smooth Muscle Cells to Collagen and their Migration toward platelet-derived growth factor", Proc. Natl. Acad. Sci. USA, Vol. 78, No. 6, pp. 3669-3672 (1991)	
		WILEY, et al., "Identification and Characterization of a new Member of the TNF Family that Induces Apoptosis", Immunity Vol. 3, 673-682 (1995)	
		KAWAKAMI, et al., "Cachectin/TNF Kills or Inhibits the Differentiation of 3T3-L1 Cells According to Developmental Stage", J. of Cellular Physiology 138:1-7 (1989)	
		KRAMMER, et al., "Apoptosis in the APO-1 system", Apoptosis: The Molecular Basis of Cell Death, pp. 87-99 (1991)	
		von Bulow, et al., "Human fetuin/a, HS glycoprotein in colloid and parenchymal cells in human fetal pituitary gland", Histochemistry, (1993) 99:13-22	
		SPIRO, "Studies on Fetuin, a glycoprotein of Fetal Serum" The Journal of Biological Chemistry, Vol. 235, No. 10, pp. 2860-2869	
		GRANT, et al., "Effects of Epidermal Growth Factor, Fibroblast Growth Factor, and Transforming Growth Factor-B on Corneal Cell Chemotaxis", Investigative Ophthalmology & Visual Science, Vol. 33, NO. 12 (1992)	
		YANG, et al., "Human a ₂ -HS-glycoprotein/bovine fetuin homologue identification and development regulation of the gene", Biochemica et Biophysica Acta 1130 (1992) 149-156	

Examiner Signature	B. CELSA	Date Considered	4/21/03
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

AUG 08 2002

RECEIVED



COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Compleat if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/902,208
		Filing Date	7/09/2001
		First Named Inventor	Tsai
		Group Art Unit	1627 1639
		Examiner Name	
Sheet 3 of 4	Attorney Docket Number	01-06-1685	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		YOSHIOKA, et al., "The Completer Amino Acid Sequence of the A-chain of Human Plasma a ₂ HS-glycoprotein, The Journal of Biological Chemistry, Vol. 261, No. 4, pp. 1665-1676 (1986)	
		GEJYO, et al., "Characterization of the B-Chain of Human Plasma a ₂ HS-Glycoprotein", The Journal of Biological Chemistry, Vol. 258 No. 8, pp. 4966-4971 (1983)	

Examiner Signature		Date Considered	7/24/03
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

AUG 08 2002

RECEIVED



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/902/208
				Filing Dat	7/09/2001
				First Named Inventor	Tsai
				Group Art Unit	1627 1639
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	01-06-1685

TECH CENTER 1600/2900

AUG 08 2002

RECEIVED

Please note that pursuant to 37 CFR 1.98(d), copies of the disclosed documents are not being provided. All information was previously cited and submitted to the Office in the prior application (09/149/878). That application (09/149/878) is relied on for an earlier filing date under 35 U.S.C. 120. In addition, the IDS submitted in that application complied with 37 CFR 1.98 (a)-(c).

B. cesa

4/2.1 23

COPY OF PAPERS
ORIGINALLY FILED